Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-09-12 DOI:10.1080/21645515.2024.2396220

Claudia Palmieri, Lorenza Moscara, Silvio Tafuri, Pasquale Stefanizzi

引用次数: 0

Abstract

Two vaccines are available to prevent serogroup B meningococcal disease, i.e. the four-component meningococcal serogroup B vaccine (4CMenB) and the bivalent-factor-H-binding-protein meningococcal s...

查看原文本刊更多论文

为出生后头两年接受免疫接种的青少年制定的 B 血清群脑膜炎球菌免疫接种政策：微型综述

目前有两种疫苗可用于预防 B 血清群脑膜炎球菌疾病，即四联 B 血清群脑膜炎球菌疫苗（4CMenB）和二价因子-H 结合蛋白脑膜炎球菌疫苗（HCB）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.